Avexitide: the GLP-1 drug that blocks it

Amylyx Pharmaceuticals said on August 18, 2026 that avexitide, its investigational GLP-1 receptor blocker, hit the main goal of a phase 3 trial called LUCIDITY in a condition known as post-bariatric hypoglycemia^[4]. Severe low blood sugar events fell 55 percent compared with placebo, a result the company called highly statistically significant^[4]. Amylyx did not build avexitide from the ground up. It bought the rights to the drug out of a 2024 bankruptcy auction for 35 million dollars, after the previous owner, Eiger BioPharmaceuticals, had already run mid-stage testing that let Amylyx move straight into a late-stage study^[3]. No medicine is currently approved anywhere for post-bariatric hypoglycemia^[2].

A GLP-1 blocker, not a booster

Every GLP-1 drug we cover on this site, including semaglutide and tirzepatide, works by activating the GLP-1 receptor. Avexitide does the opposite. It is a competitive GLP-1 receptor antagonist, also known by the research name exendin(9-39), and it binds the same receptor without turning it on^[1]. That single difference explains why avexitide exists at all. Post-bariatric hypoglycemia is thought to involve too much GLP-1 signaling after a meal, not too little, so a drug that dials that signal down is a plausible fix in a way that adding more GLP-1 activity would not be^[2]. A reader coming from our semaglutide or tirzepatide coverage should not assume avexitide sits in the same treatment category. It sits across the table from it.

Why gastric bypass can cause dangerous low blood sugar

Post-bariatric hypoglycemia mostly follows Roux-en-Y gastric bypass surgery. Food reaches the small intestine faster than it would through an intact stomach, so blood glucose spikes higher after a meal and then drops lower afterward. That faster transit pushes GLP-1 release up, which triggers an exaggerated burst of insulin. At the same time, levels of ghrelin, a hormone that normally restrains insulin release, fall after the surgery, removing one of the body's own brakes. The beta cells that make insulin also do not shut off quickly enough once glucose starts to fall, and the hormones that would normally counter a glucose crash respond less forcefully than they should.[2] Symptoms usually show up one to three hours after eating, especially after a meal heavy in refined carbohydrate. They range from shaking, sweating and a racing heart to confusion, slurred speech and, in the more severe cases, seizures or loss of consciousness.[2] Amylyx puts the estimated U.S. population living with the condition at around 160,000 people, roughly 8 percent of everyone who has had bariatric surgery.[4]

What the LUCIDITY trial found

LUCIDITY enrolled 78 adults with post-bariatric hypoglycemia after Roux-en-Y gastric bypass at 21 sites in the United States^[4]. Participants were randomly assigned, in a 3 to 2 ratio, to either avexitide or placebo, and neither the participants nor the study team knew who received which during the treatment period. After a screening window of up to six weeks, the trial administered avexitide 90 mg by daily subcutaneous injection for 16 weeks, followed by an open-label extension that is still running^[1]. The FDA agreed with Amylyx in advance on the primary measure: the combined rate of Level 2 and Level 3 hypoglycemic events, the two most serious tiers on the standard hypoglycemia scale^[1].

Every secondary measure moved the same direction: events tracked by self-monitored blood glucose, events tracked by continuous glucose monitors, and the most severe Level 3 events all fell by a wide, statistically significant margin^[4]. Safety looked ordinary for an injectable peptide. The most common side effects were diarrhea and mild reactions at the injection site, most of them mild or moderate, and Amylyx reported no serious adverse events tied to the drug and no change in body weight in either arm over the 16 weeks^[4]. Marilyn Tan, the trial's principal investigator and a clinical professor at Stanford School of Medicine, framed the stakes plainly: Level 2 and Level 3 events can be medical emergencies, capable of causing seizures, loss of consciousness or the need for someone else to step in and help^[4].

What the trial does not yet show

Read the topline numbers for what they are. Seventy-eight people is a small trial by phase 3 standards, and it enrolled only patients whose hypoglycemia followed Roux-en-Y gastric bypass. Sleeve gastrectomy, a different and more common bariatric procedure, also causes post-bariatric hypoglycemia in some patients, and LUCIDITY does not tell us whether avexitide works the same way for them.[1] The open-label extension that would answer the longer-term safety question has not finished, and Amylyx has released topline numbers, not a peer-reviewed paper. Before avexitide, the available options were all used off label: diet changes built around low glycemic index carbohydrates, plus drugs such as acarbose, somatostatin analogs and diazoxide, none of which was designed for this indication.[2]

Why FDA approval is not guaranteed

The FDA previously granted avexitide breakthrough therapy designation for post-bariatric hypoglycemia^[4]. That status can speed up the review process and gets the sponsor more frequent contact with the agency, but it does not promise a yes. Amylyx said it plans to file a new drug application by the end of 2026 and, if the FDA approves it, aims to launch avexitide in 2027^[4]. Analysts covering the stock have floated peak annual sales as high as 1.3 to 1.5 billion dollars, a number worth treating as a projection built on one topline readout rather than a settled fact^[3]. For comparison, readers can see how a full FDA review plays out on our tirzepatide regulation page, which tracks Mounjaro and Zepbound through their own approval and labeling history.

Where avexitide fits among the GLP-1 drugs we cover

Most of what we publish about GLP-1 biology involves drugs that turn the receptor up: semaglutide for diabetes and weight loss, tirzepatide for the same pair of uses plus sleep apnea. Avexitide shows the same biology running in the other direction: gastric bypass surgery, sometimes performed to help patients lose weight, can leave some of them with an insulin response the body cannot switch off fast enough. If avexitide reaches the market, it will not compete with semaglutide or tirzepatide. It will sit downstream of them, treating a complication surgery caused in the first place. Anyone with symptoms of low blood sugar after bariatric surgery should raise it with the team managing their care rather than wait on a drug that has not reached the FDA.